| Literature DB >> 26402664 |
Li-Ping Dai1,2,3, Chun Li4,5, Han-Ze Yang6, Yan-Qing Lu7,8, Hong-Yan Yu9, Hui-Min Gao10,11, Zhi-Min Wang12,13.
Abstract
Three types of ent-kaurane diterpenoids were isolated from the aerial parts of Isodon excisoides, including three new diterpenoids, 1α,7α,14β-trihydroxy-20-acetoxy-ent-kaur-15-one (1); 1α,7α,14β,18-tetrahydroxy-20-acetoxy-ent-kaur-15-one (2); and 1α-acetoxy-14β-hydroxy-7α,20-epoxy-ent-kaur-16-en-15-one (3); together with six known diterpenes henryin (4); kamebanin (5); reniformin C (6); kamebacetal A (7); kamebacetal B (8); and oridonin (9). The structures of the isolated compounds were elucidated by means of nuclear magnetic resonance spectroscopy and high-resolution mass spectrometry in conjunction with published data for their analogs, as well as their fragmentation patterns. Compounds 5 and 9 were isolated from Isodon excisoides for the first time. To explore the structure-activity relationships of the isolated compounds, they were tested for their cytotoxic effects against five human cancer cell lines: HCT-116, HepG2, A2780, NCI-H1650, and BGC-823. Most of the isolated compounds showed certain cytotoxic activity against the five cancer cell lines with IC50 values ranging from 1.09-8.53 µM. Among the tested compounds, compound 4 exhibited the strongest cytotoxic activity in the tested cell lines, with IC50 values ranging from 1.31-2.07 µM. Compounds 1, 6, and 7 exhibited selective cytotoxic activity.Entities:
Keywords: Isodon excisoides; cytotoxic activity; ent-kaurane diterpene; structure-activity relationship
Mesh:
Substances:
Year: 2015 PMID: 26402664 PMCID: PMC6332174 DOI: 10.3390/molecules200917544
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Structures of compounds 1–9.
1H- and 13C-NMR data of compounds 1–3 (500 and 125 MHz δ in ppm).
| No. | 1 (In CDCl3) | 2 (In DMSO- | 3 (In CDCl3) | |||
|---|---|---|---|---|---|---|
| δH ( | δC | δH ( | δC | δH ( | δC | |
| 1 | β 3.31, dd, (11.0, 4.6) | 81.6 | β 3.09, dd, (10.8, 4.5) | 80.5 | β 4.57, dd, (11.2, 5.3) | 76.6 |
| 2 | α 1.82, m | 30.5 | α 1.63, overlapped | 29.2 | α 1.69, overlapped | 25.1 |
| β 1.65, overlapped | β 1.53, overlapped | β 1.47, m | ||||
| 3 | α 1.47, dt, (13.8, 3.7) | 39.4 | α 1.53, overlapped | 32.9 | α 1.44, m | 37.9 |
| β 1.29, dt, (13.8, 4.4) | β 1.05, m | β 1.24, m | ||||
| 4 | – | 32.9 | – | 36.6 | – | 33.6 |
| 5 | β 0.98, dd, (11.6, 3.5) | 52.5 | β 1.21, d, (12.2) | 42.0 | β 1.33, ddd, (11.8, 7.4, 1.5) | 47.1 |
| 6 | 1.93, m | 28.6 | β 1.80, d, (12.2) | 28.6 | β 2.85, ddd, (14.0, 11.8, 1.9) | 25.1 |
| α 1.63, overlapped | α 1.84, overlapped | |||||
| 7 | β 4.20, dd (11.4, 6.0) | 75.4 | β 3.77, dd, (11.8, 4.3) | 73.8 | β 3.95, dd, (3.8, 1.9) | 64.5 |
| 8 | – | 61.0 | – | 59.8 | – | 58.7 |
| 9 | β 1.55, d, (8.8) | 55.5 | β 1.37, d, (8.6) | 55.7 | β 1.69, overlapped | 50.8 |
| 10 | – | 46.0 | – | 44.1 | – | 39.2 |
| 11 | α 2.77, q, (6.1) | 19.9 | α 2.82, dd, (15.9, 5.6) | 19.3 | α 1.84, overlapped | 17.8 |
| β 1.20, m | β 0.98, m | β 1.15, q, (6.5) | ||||
| 12 | α 1.88, m | 24.2 | α 1.63, overlapped | 24.3 | α 2.42, dt, (14.1, 9.0) | 30.9 |
| β 1.65, overlapped | β 1.53, overlapped | β 1.54, m | ||||
| 13 | α 2.42, m | 42.4 | α 2.24, m | 42.5 | α 2.99, br d, (9.9) | 42.0 |
| 14 | α 4.82, d, (1.1) | 76.1 | α 4.72, br. s | 75.2 | α 4.61, br s | 71.5 |
| 15 | – | 222.8 | – | 221.2 | – | 204.5 |
| 16 | 2.88, m | 43.2 | 2.67, m | 44.6 | – | 151.1 |
| 17 | 1.12, d, (7.1) | 9.2 | 1.00, d, (7.1) | 9.1 | 6.00, br s; 5.38, br.s | 117.5 |
| 18 | 0.91, s | 33.3 | 3.19, d, (10.6) | 69.5 | 0.88, s | 31.4 |
| 2.84, d, (10.6) | ||||||
| 19 | 0.85, s | 21.5 | 0.62, s | 17.3 | 1.08, s | 20.3 |
| 20 | α 4.74, d, (13.2) | 63.7 | α 4.35, d, (13.3) | 64.1 | α 4.09, dd, (10.3, 1.5) | 61.0 |
| β 4.37, d, (13.2) | β 4.28, d, (13.3) | β 4.03, dd, (10.3, 1.6) | ||||
| OAc | – | 170.8 | – | 170.2 | – | 170.1 |
| OAc | 2.13, s | 21.5 | 2.07, s | 21.2 | 1.95, s | 21.5 |
Figure 2Key HMBC and 1H-1HCOSY correlations for compounds 1–3.
Figure 3Key ROESY correlations for compounds 1–3.
Figure 4Experimental CD spectra of compounds 1 and 2.
Cytotoxic activities of all tested compounds on five human cancer cell lines.
| Sample | IC50 (μM) | ||||
|---|---|---|---|---|---|
| HCT-116 | HepG2 | BGC-823 | NCI-H1650 | A2780 | |
| 1 | 2.94 ± 0.06 | 3.07 ± 0.02 | 5.59 ± 0.19 | >10 | 6.33 ± 0.34 |
| 2 | 2.45 ± 0.12 | 3.21 ± 0.09 | 4.17 ± 0.25 | >10 | 5.61 ± 0.19 |
| 3 | 2.13 ± 0.81 | 2.20 ± 1.12 | >10 | 5.68 ± 0.73 | 1.09 ± 0.13 |
| 4 | 1.77 ± 0.22 | 1.54 ± 0.32 | 1.31 ± 0.76 | 2.07 ± 0.36 | 1.42 ± 0.20 |
| 5 | 4.85 ± 0.33 | 7.88 ± 1.02 | 2.99 ± 0.76 | >10 | 1.56 ± 0.34 |
| 6 | 4.81 ± 0.01 | 7.45 ± 0.22 | 5.17 ± 0.61 | >10 | 1.98 ± 0.13 |
| 7 | 4.87 ± 1.12 | 1.09 ± 0.06 | 5.31 ± 0.14 | 2.58 ± 0.23 | 1.44 ± 0.07 |
| 8 | 4.55 ± 0.02 | 7.35 ± 0.48 | 4.97 ± 0.84 | 2.38 ± 0.31 | 4.88 ± 0.22 |
| 9 | 4.85 ± 0.33 | 7.88 ± 1.02 | 2.99 ± 0.76 | >10 | 1.56 ± 0.34 |
| DDP | 7.81 ± 0.14 | >10 | 8.56 ± 1.05 | >10 | 8.65 ± 0.59 |
| Taxol | (3.07 ± 0.12) × 10−2 | (1.31 ± 0.44) × 10−2 | (4.06 ± 0.35) × 10−3 | (2.61 ± 1.02) × 10−2 | (7.13 ± 0.51) × 10−3 |
DDPH (cisplatin) and taxol were used as positive controls.